Dipeptidyl peptidase 4 (DPP-4) inhibitors for people with chronic kidney disease and diabetes-Reference-Cited by-同舟云学术

Dipeptidyl peptidase 4 (DPP-4) inhibitors for people with chronic kidney disease and diabetes

Published:2023-08-29 Issue:8 Volume:2023 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Natale Patrizia¹²³,Palmer Suetonia C⁴,Tunnicliffe David J¹,Toyama Tadashi⁵,Strippoli Giovanni FM¹⁶

Affiliation:

1. Sydney School of Public Health; The University of Sydney; Sydney Australia

2. Nephrology, Dialysis and Transplantation Unit, Department of Medical and Surgical Sciences; University of Foggia; Foggia Italy

3. Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE-J); University of Bari Aldo Moro; Bari Italy

4. Department of Medicine; University of Otago Christchurch; Christchurch New Zealand

5. Department of Nephrology and Laboratory Medicine; Kanazawa University; Kanazawa Japan

6. Department of Precision and Regenerative Medicine andIonian Area (DIMEPRE-J); University of Bari Aldo Moro; Bari Italy

Publisher

Wiley

Subject

Pharmacology (medical)

Reference38 articles.

1. Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism;Ahrén;Diabetologia,2016

2. McDonald S Excell L Dent H ANZDATA 32nd Annual Report. 2009 Report: Data to 2008. Chapter 2: New patients commencing treatment in 2008 www.anzdata.org.au/report/anzdata-32nd-annual-report-2009/

4. Type 2 diabetes [Erratum in: Lancet. 2017 Jun 3;389(10085):2192];Chatterjee;Lancet,2017

5. Excerpts from the United States Renal Data System 2007 Annual Data Report;Collins;American Journal of Kidney Diseases,2008